Articles
-
4 days ago |
mddionline.com | Omar Ford
Abbott Laboratories, Dexcom, and Medtronic are three of the biggest names in continuous glucose monitoring. But Senseonics is gaining momentum in the space. Through its commercial partnership with Ascensia Diabetes Care, the Germantown, MD-based company is becoming a bigger name in CGMs and reporting strong earnings during a turbulent time in the economy. The company reported revenue of $6.3 million, which was well above the consensus of $5.4 million.
-
1 week ago |
mddionline.com | Omar Ford
Staar Surgical, a company that develops phakic IOLs, is withdrawing its 2025 guidance that was announced in February, citing global economic uncertainty and tariff policy conditions."The Lake Forest, CA-based company reported net sales of $42.6 million for 1Q25 compared to $77.4 million in the prior year quarter.
-
1 week ago |
mddionline.com | Omar Ford |Bioworld Medtech
Omar Ford is a seasoned journalist specializing in medical technology, healthcare innovation, and the medical device and diagnostics industry. As the editor-in-chief of Medical Device + Diagnostics Industry (MD+DI), he has earned a reputation as a leading authority in the field, offering in-depth insights into the latest trends, regulatory changes, and technological advancements shaping the future of healthcare. Omar has been a featured speaker at MD&M and MEDevice events.
-
1 week ago |
mddionline.com | Omar Ford
Later this year, companies will get a chance to get their hands on Zenda, an Saas that is poised to redefine operational planning and management. MD+DI spoke with Harold Hambrose - Chief Strategy Officer at Zenda, to see how the platform will enhance business operations models. Could you talk a little bit about why Zenda was formed? What specific need are you trying to meet?
-
1 week ago |
mddionline.com | Omar Ford
Integra had some struggles in 2024 with layoffs and cutting its guidance. How did it fare in 1Q25. Last year was a trying time for Integra LifeSciences. The Princeton, NJ-based company suffered from quality control issues, which led to the firm lowering its full-year guidance. Now the company has reported on its 1Q25 earnings. Did it make it through last year’s troubles? The answer is yes and no.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 230
- Tweets
- 1K
- DMs Open
- No
Abbott’s Volt PFA system shows strong 12-month data: 83.5% PAF & 58.1% PersAF patients arrhythmia-free, just 2.7% safety events. With CE mark secured, FDA filing is next. The PFA race just got tighter. https://t.co/RaDJYoEamx #Medtech #Electrophysiology
https://t.co/mHT8VFRpRt
Is @AbbottNews a beacon of hope during the #tariff conflict? See what the company's 2025 guidance reveals about its tariff strategy. @MDDIonline #medtech https://t.co/2miRobJVRI